- ICH GCP
- US Clinical Trials Registry
- Search trials
Clinical Trials on High Risk Smoldering Multiple Myeloma in United States
Total 2361 results
-
Boston Children's HospitalCompletedCoronary Artery Disease Risk HighUnited States
-
University of PennsylvaniaGenentech, Inc.Recruiting
-
University of ChicagoGlaxoSmithKline; AmgenRecruitingMultiple Myeloma | Relapse Multiple MyelomaUnited States
-
University of Colorado, DenverNational Cancer Institute (NCI); Karyopharm Therapeutics IncRecruitingMultiple Myeloma in RelapseUnited States
-
University of Maryland, BaltimoreActive, not recruitingRelapsed/Refractory Multiple MyelomaUnited States
-
Abramson Cancer Center of the University of PennsylvaniaCompleted
-
University of PittsburghNovartisWithdrawnMultiple Myeloma | Multiple Myeloma in RelapseUnited States
-
Rapa Therapeutics LLCMedical College of WisconsinRecruitingRelapsed, Refractory Multiple MyelomaUnited States
-
Larysa SanchezJanssen, LPRecruitingNewly Diagnosed Multiple MyelomaUnited States
-
Case Comprehensive Cancer CenterCompletedRefractory Multiple MyelomaUnited States
-
Dana-Farber Cancer InstituteBristol-Myers SquibbNo longer availableMultiple Myeloma | Multiple Myeloma in RelapseUnited States
-
Attaya SuvannasankhaNational Cancer Institute (NCI)TerminatedRefractory Multiple MyelomaUnited States
-
Celyad Oncology SANational Heart, Lung, and Blood Institute (NHLBI); Dana-Farber Cancer InstituteCompletedAcute Myeloid Leukemia | Multiple Myeloma | Myelodysplastic SyndromeUnited States
-
Boston Scientific CorporationRecruitingHeart Disease, Coronary | High-risk Percutaneous Coronary InterventionUnited States, Sweden
-
Gilead SciencesCompletedChronic Lymphocytic Leukemia (CLL) | Acute Myeloid Leukemia (AML) | Multiple Myeloma (MM) | Lymphoma, Non-Hodgkin (NHL)United States
-
Acerta Pharma BVAcerta Pharma, LLCCompletedMultiple Myeloma (MM)United States, United Kingdom
-
Brigham and Women's HospitalNational Institute of Mental Health (NIMH); Yale University; OrygenRecruitingPsychosis | Remission | Conversion | Clinical High RiskUnited States, United Kingdom, Canada, Italy, Australia, Chile, China, Denmark, Germany, Hong Kong, Korea, Republic of, Singapore, Spain, Switzerland
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)TerminatedRefractory Multiple MyelomaUnited States
-
Ascentage Pharma Group Inc.RecruitingAcute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Myelomonocytic Leukemia | AML | MDS | CMML | High-risk Myelodysplastic SyndromeUnited States
-
Aptose Biosciences Inc.TerminatedAcute Myelogenous Leukemia | Acute Myelogenous Leukemia in Relapse | Acute Myelogenous Leukemia, Relapsed, Adult | Acute Myelogenous Leukemia, Adult | High Risk MyelodysplasiaUnited States
-
OncotherapeuticsKaryopharm Therapeutics IncRecruitingRefractory Multiple MyelomaUnited States
-
OncotherapeuticsTakedaTerminatedNewly Diagnosed Multiple MyelomaUnited States
-
National Cancer Institute (NCI)CompletedRefractory Multiple MyelomaUnited States
-
University of California, San DiegoTakeda; Celgene; Janssen, LPActive, not recruitingRelapsed/Refractory Multiple MyelomaUnited States
-
LifeTime PharmaceuticalsUnknownMultiple Myeloma and Plasma Cell Neoplasm | Precancerous ConditionUnited States
-
Vincerx Pharma, Inc.RecruitingAcute Myeloid Leukemia | B-cell Acute Lymphoblastic Leukemia | High-risk Myelodysplastic SyndromeUnited States
-
Dana-Farber Cancer InstituteEli Lilly and CompanyRecruitingBreast Cancer | Early-stage Breast Cancer | High Risk Breast CarcinomaUnited States
-
University of IowaCompleted
-
Adriana RossiNot yet recruitingRelapsed and/or Refractory Multiple MyelomaUnited States
-
Massachusetts General HospitalSanofi; GlaxoSmithKlineNot yet recruitingMultiple Myeloma | Refractory Multiple Myeloma | Relapsed CancerUnited States
-
NYU Langone HealthCelgene CorporationTerminatedRelapsed or Refractory Multiple MyelomaUnited States
-
Novartis PharmaceuticalsCompletedMultiple Myeloma Bone DiseaseUnited Kingdom, United States
-
Rene KahnCompletedUltra High Risk for PsychosisSpain, Austria, Germany, Israel, Italy, Netherlands, Norway, Switzerland, United Kingdom
-
PDS Biotechnology Corp.CompletedHigh-risk HPV Infection and Biopsy-proven CIN1United States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingHigh Risk Myelodysplastic SyndromeUnited States
-
Virginia Commonwealth UniversityNational Cancer Institute (NCI)CompletedLymphoma | Leukemia | Multiple Myeloma and Plasma Cell Neoplasm | Drug/Agent Toxicity by Tissue/OrganUnited States
-
Kathleen DorritieBristol-Myers SquibbRecruitingRelapsed and Refractory Multiple MyelomaUnited States
-
Pack HealthM.D. Anderson Cancer Center; Sanofi; University of WashingtonRecruitingMultiple Myeloma | Refractory Multiple MyelomaUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedRefractory Multiple MyelomaUnited States, Italy
-
Novartis PharmaceuticalsTerminated
-
National Cancer Institute (NCI)WithdrawnRefractory Plasma Cell Myeloma | DS Stage I Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell MyelomaUnited States
-
Sidney Kimmel Comprehensive Cancer Center at Johns...Stand Up To CancerRecruitingMutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic CancerPancreatic Cancer | High Risk CancerUnited States
-
AmgenCompletedRefractory Multiple Myeloma | Relapsed Multiple MyelomaCanada, Belgium, Spain, United States, Korea, Republic of, Australia, Czechia, Taiwan, Hungary, Austria, Romania, Japan, United Kingdom, Greece, Turkey, Bulgaria, France, Russian Federation, Poland
-
Janssen Research & Development, LLCWithdrawnRelapsed/ Refractory Multiple MyelomaUnited States, Poland
-
Massachusetts General HospitalDana-Farber Cancer Institute; Beth Israel Deaconess Medical CenterCompletedLymphoma | Multiple Myeloma | Acute Myelogenous LeukemiaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedRefractory Plasma Cell Myeloma | DS Stage I Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell MyelomaUnited States
-
National Cancer Institute (NCI)CompletedRefractory Plasma Cell Myeloma | DS Stage I Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell MyelomaUnited States
-
University of LeedsKaryopharm Therapeutics Inc; Myeloma UKWithdrawnMyeloma MultipleUnited Kingdom
-
Emory UniversityNational Cancer Institute (NCI); Merck Sharp & Dohme LLC; National Institutes...CompletedRefractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | ISS Stage III Plasma Cell Myeloma | ISS Stage II Plasma Cell Myeloma | ISS Stage I Plasma Cell MyelomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingUntreated Adult Acute Myeloid Leukemia | Myelodysplastic Syndrome With Excess Blasts | High Risk Myelodysplastic Syndrome | de Novo Myelodysplastic Syndrome | Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1 | Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 | Acute Myeloid... and other conditionsUnited States